CClinicalTrials.gg
Status unknownNCT03406988ADUL-SScUpdated Jan 25, 2018

Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers

An interventional study of Autologous fat grafting and Sham procedure in Systemic Sclerosis and Digital Ulcer, sponsored by ASST Gaetano Pini-CTO. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-01-25.

Sponsored by ASST Gaetano Pini-CTO · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A randomized controlled trial will be performed to confirm preliminary uncontrolled data indicating that regional adipose tissue grafting is effective in inducing digital ulcer healing in patients with systemic sclerosis.

Systemic Sclerosis patients with digital ulcers will be randomized to be blindly treated with adipose tissue implantation or a sham procedure. Adipose tissue grafting will consist of injection at the base of the finger with digital ulcer of 0.5-1 ml of adipose tissue after centrifugation of fat aspirate. Sharm procedure will consist of false liposuction and local injection of saline solution.

The primary end-point will be to compare the cumulative prevalence of healed digital ulcers in the two groups within the following 8 weeks.

Read the detailed description

Systemic sclerosis (SSc) is an autoimmune disease characterized by a multifactorial pathological process where a central role is played by the progressive loss of the microvascular bed, with the consequent fibrotic changes in the involved organs and tissues.

The most advanced stages of capillary loss may induce the formation of digital ulcers (DUs) on the fingertips.The healing of DUs is often a lengthy process requiring accurate and intensive topical and systemic treatment. Nevertheless, in a significant number of cases this therapeutic approach is ineffective and distal necrosis with subsequent tissue loss or phalangeal amputation may eventually occur.

In a recent open pilot study performed by Del Papa et al., it has been demonstrated that autologous adipose tissue grafting (AT-G), which is known to contain both adipose-derived stem cells and a stromal/vascular fraction, was effective in inducing prompt healing of long lasting DUs localized in the fingertips of a small number of patients with SSc. The DU healing was accompanied by the rapid disappearance of local ischemic pain and evidence of a partial restoration of the capillary bed in the digits when assessed by nailfold videocapillaroscopy (NVC).

With the purpose of confirming these preliminary results, the investigators have designed a monocentric randomized controlled study. In accordance with the study protocol, patients with a typical SSc-related DU on the fingertip will be randomized to undergo a regional AT-G with autologous fat as active therapy or a 'sham' procedure (SP) - that simulates the active treatment - as placebo treatment. All of the patients with SSc enrolled in both arms will be blind regarding the treatment received. Furthermore, during the study period all of the enrolled patients will receive the same systemic vasoactive and topical therapy.

02

Conditions studied

  • Systemic Sclerosis
  • Digital Ulcer

Keywords

  • Systemic Sclerosis
  • Digital Ulcer
  • Autologous fat grafting
  • Adipose tissue stem cells
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients candidate for enrollment in the study have to meet the 2013 classification criteria of the American College of Rheumatology/European League Against Rheumatism for SSc;
  • Patients may have either the limited cutaneous or the diffuse cutaneous variants of SSc;
  • All of the candidate patients must have only one active DU (cardinal ulcer), lasting for at least 6 weeks prior to enrolment time and showing no tendency to heal despite intravenous iloprost (0.5-2 ng/Kg/min), the oral administration of calcium-channel blockers (nifedipine) and local medication with surgical removal of necrotic tissue.

Exclusion criteria

Exclusion Criteria:

  • Presence of severe extra-cutaneous manifestations, such as cardiac, lung and renal involvement;
  • Concomitant treatment with immune-suppressive therapies (including prednisone equivalent >10 mg);
  • Current therapy with dual and selective endothelin inhibitors;
  • Concomitant diabetes and/or other vascular diseases;
  • Current pregnancy or breastfeeding.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Autologous fat grafting

    Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.

    Procedure: Autologous fat grafting

  • Placebo comparator
    Sham procedure

    False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.

    Procedure: Sham procedure

Interventions

  • ProcedureAutologous fat grafting

    Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU

    Also known as: Iloprost infusion, oral nifedipine

  • ProcedureSham procedure

    Local injection of 0.5ml saline solution after a simulated liposuction procedure.

    Also known as: Iloprost infusion, oral nifedipine

05

What researchers measure

Primary outcomes

  1. Digital Ulcer healing

    Prevalence of DU healing in the arm treated with autologous fat grafting in comparison with the prevalence of healing in the placebo group.

    Time frame: 8 weeks after either autologus fat grafting or sham procedure.

Secondary outcomes

  1. Pain evaluation by Visual Analogue Scale (VAS)

    The pain VAS is a continuous scale comprised of a horizontal line of 10 centimeters (100 mm) in length, ranging from 0 (minimum= no pain) to 100 (worst imaginable pain). The respondents will be asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. In this study VAS score will be used to measure the decrease (or resolution) of pain with respect to baseline value in patients who will undergo treatment with autologous fat grafting (active arm) in comparison with patients of the placebo group.

    Time frame: This evaluation will be done at baseline and at the 2nd, 4th, 6th, 8th week after interventions (either autologus fat grafting or sham procedure).

  2. Neovascularization evaluation

    Increase of the number of capillaries assessed by NVC in the affected digit of patients treated with autologous fat grafting in comparison with patients of the placebo group.

    Time frame: Baseline and 8 weeks after either autologus fat grafting or sham procedure.

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7;360(19):1989-2003. doi: 10.1056/NEJMra0806188. No abstract available. PubMed 19420368 ↗
  • Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii19-24. doi: 10.1093/rheumatology/kep105. PubMed 19487218 ↗
  • Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, Fraticelli P, Moroncini G, Beretta L, Santaniello A, Sambataro G, Ferraresi R, Vitali C. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant. 2015;24(11):2297-305. doi: 10.3727/096368914X685636. Epub 2014 Dec 12. PubMed 25506730 ↗
  • Del Papa N, Di Luca G, Andracco R, Zaccara E, Maglione W, Pignataro F, Minniti A, Vitali C. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019 Jan 7;21(1):7. doi: 10.1186/s13075-018-1792-8. PubMed 30616671 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03406988
Lead sponsor
ASST Gaetano Pini-CTO
Collaborators
Società Italiana di Reumatologia
Responsible party
Nicoletta Del Papa (MD, Head of the Scleroderma Clinics, Rheumatology Department, ASST Gaetano Pini-CTO) — Principal investigator
First posted
Jan 23, 2018
Start date
Jul 18, 2017
Primary completion
Mar 31, 2018 (estimated)
Completion
Mar 31, 2018 (estimated)
Last update
Jan 25, 2018

Study contacts

Nicoletta Del Papa, MD
Contact
nicoletta.delpapa@asst-pini-cto.it
+39-0258296415
Claudio Vitali, MD
Contact
c.vitali@yahoo.it
+39-0258296415
Nicoletta Del Papa, MD
principal investigator · ASST Gaetano Pini-CTO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion